DOCSLIB.ORG

TOPICAL CORTICOSTEROIDS Alcovate Cream, Ointment 0.05%

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TOPICAL CORTICOSTEROIDS Alcovate Cream, Ointment 0.05% TOPICAL CORTICOSTEROIDS Locoid Cream, Lipocream, Lotion, Ointment, Alcovate Cream, Ointment 0.05% Solution 0.1% (alclometasone dipropionate) (hydrocortisone butyrate) Apexicon E Cream 0.05% Luxiq Foam 0.12% (diflorasone diacetate) (betamethasone valerate) Ala Scalp Lotion 2% Micort-HC Cream 2.5% (hydrocortisone) (hydrocortisone acetate) Capex Shampoo 0.01% Nolix Cream, Lotion 0.05% (fluocinolone acetonide) (flurandrenolide) Olux Foam 0.05% Cloderm Cream 0.10% Olux E Emulsion Foam 0.05% (clocortolone pivalate) (clobetasol propionate) Clobex Lotion, Shampoo, Spray 0.05% Pandel Cream 0.1% Clodan Shampoo 0.05% (hydrocortisone probutate) (clobetasol propionate) Cordran Cream 0.025% Cordran Cream, Lotion, Ointment 0.05% Psorcon Cream, Ointment 0.05% Cordran Tape 4mcg (diflorasone) (flurandrenolide) Cormax Solution 0.05% Sernivo Spray 0.05% (clobetasol propionate) (betamethasone dipropionate) Cutivate Cream, Lotion 0.05% Synalar Cream, Ointment, Solution 0.01% Cutivate Ointment 0.005% Synalar Cream, Ointment 0.025% (fluticasone propionate) (fluocinolone acetonide) Temovate-E Cream 0.05% Cyclocort Cream, lotion, Ointment 0.1% Temovate Cream, Gel, Ointment, Solution (amcinonide) 0.05% (clobetasol propionate) Derma-smooth /FS body oil 0.01% Texacort Solution 2.5% Derma-smooth /FS scalp oil 0.01% (hydrocortisone) (fluocinolone acetonide) Topicort Cream, Gel, Ointment, Spray Dermatop Cream, Ointment 0.1% 0.05% 0.25% (prednicarbate) (desoximetasone) Triamcinolone Cream, Lotion, Ointment, Desonate Gel 0.05% Spray 0.025%, 0.05%, 0.1%, 0.5% Desonide Cream Lotion, Ointment 0.05% Triderm Cream 0.1%, 0.5% Desowen Lotion 0.05% Kenalog aerosol spray 0.147 mg/ml (desonide) (triamcinolone acetonide) Diprosone Cream, Lotion, Ointment 0.05% Tridesilon Cream 0.05% Diprolene AF Cream, Gel, Lotion, Verdeso Foam 0.05% Ointment 0.05% (desonide) (betamethasone dipropionate) Elocon Cream, Ointment, Solution 0.1% Trianex* Ointment 0.05% (mometasone furoate) (triamcinolone acetonide) Topical Corticosteroids FEP Clinical Criteria Halog Cream, Ointment, Solution 0.1% Ultravate Cream, Lotion, Ointment 0.05% (halcinonide) (halobetasol propionate) Hydrocortisone Cream, Lotion, Ointment Wescort Cream, Ointment 0.2% 1%, 2.5% (hydrocortisone valerate) Impeklo Lotion 0.05% Valisone Cream, Lotion, Ointment 0.01% (clobetasol propionate) (betamethasone valerate) Vanos* Cream, Gel, Ointment, Solution Impoyz Cream 0.025% 0.1% (clobetasol propionate) (fluocinonide) Lidex E Cream 0.05% Verdeso Foam 0.05% Lidex Gel, Ointment, Solution, Cream (desonide) 0.05% (fluocinonide) *Prior authorization for certain non-covered formulations applies only to formulary exceptions _________________________________________________________________________________________________________________________ Pre - PA Allowance Quantity ALCLOMETASONE 3 MONTH Strength UOM Potency DIPROPIONATE LIMIT ALCLOMETASONE Low to 0.05% GM 460 CREAM Medium ALCLOMETASONE Low to 0.05% GM 460 OINTMENT Medium 3 MONTH AMCINONIDE Strength UOM Potency LIMIT AMCINONIDE 0.1% GM High 460 CREAM AMCINONIDE 0.1% ML High 460 LOTION AMCINONIDE 0.1% GM High 460 OINTMENT BETAMETHASONE 3 MONTH Strength UOM Potency DIPROPIONATE LIMIT SERNIVO 0.05% ML Medium 460 SPRAY BETAMETHASONE DIPROPIONATE 0.05% GM Medium 460 CREAM BETAMETHASONE DIPROPIONATE 0.05% ML Medium 460 LOTION BETAMETHASONE DIPROPIONATE Very 0.05% GM 460 OINTMENT high DIPROLENE AF 0.05% GM AUGMENTED CREAM High 460 BETAMETHASONE DIPROPIONATE 0.05% GM AUGMENTED CREAM BETAMETAMETHASONE DIPROPIONATE Very AUGMENTED 0.05% GM 460 high GEL Topical Corticosteroids FEP Clinical Criteria BETAMETAMETHASONE DIPROPIONATE Very AUGMENTED 0.05% ML 460 high LOTION DIPROLENE 0.05% GM AUGMENTED OINTMENT Very 460 BETAMETHASONE DIPROPIONATE high 0.05% GM AUGMENTED OINTMENT BETAMETHASONE 3 MONTH Strength UOM Potency VALERATE LIMIT BETAMETHASONE VALERATE 0.1% GM Medium 460 CREAM LUXIQ 0.12% GM AEROSOL FOAM Medium 460 BETAMETHASONE VALERATE 0.12% GM AEROSOL FOAM BETAMETHASONE VALERATE 0.1% ML Medium 460 LOTION BETAMETHASONE VALERATE 0.1% GM Medium 460 OINTMENT CLOBETASOL 3 MONTH Strength UOM Potency PROPIONATE LIMIT CLOBEX 0.05% ML SPRAY Very 460 CLOBETASOL high 0.05% ML SPRAY CORMAX 0.05% ML SOLUTION High 460 TEMOVATE 0.05% ML SOLUTION IMPOYZ 0.025% GM High 460 CREAM TEMOVATE 0.05% GM CREAM Very 460 CLOBETASOL high 0.05% GM CREAM OLUX 0.05% GM AEROSOL FOAM Very 460 CLOBETASOL high 0.05% GM AEROSOL FOAM CLOBETASOL Very 0.05% GM 460 GEL high CLOBEX 0.05% ML LOTION Very 460 CLOBETASOL high 0.05% ML LOTION TEMOVATE 0.05% GM OINTMENT Very 460 CLOBETASOL high 0.05% GM OINTMENT CLOBEX Very 0.05% ML 460 SHAMPOO high Topical Corticosteroids FEP Clinical Criteria CLODAN 0.05% ML SHAMPOO CLOBETASOL E Very 0.05% GM 460 EMOLLIENT CREAM high OLUX-E 0.05% GM AEROSOL EMULSION FOAM Very 460 CLOBETASOL high 0.05% GM AEROSOL EMULSION FOAM Very IMPEKLO LOTION 0.05% GM 460 high CLOCORTOLONE 3 MONTH Strength UOM Potency PIVALATE LIMIT CLODERM 0.10% GM CREAM Medium 460 CLOCORTOLONE 0.10% GM CREAM 3 MONTH DESONIDE Strength UOM Potency LIMIT DESOWEN 0.05% GM Low to CREAM Medium DESONIDE 0.05% GM CREAM 460 TRIDESILON 0.05% GM CREAM Low DESONIDE 0.05% GM CREAM VERDESO 0.05% GM Low 460 AEROSOL FOAM DESONATE 0.05% GM Low 460 GEL DESOWEN 0.05% ML LOTION Low to 460 DESONIDE Medium 0.05% ML LOTION DESONIDE 0.05% GM Low 460 OINTMENT 3 MONTH DESOXIMETASONE Strength UOM Potency LIMIT TOPICORT 0.25% ML High to SPRAY Very 460 DESOXIMETASONE 0.25% ML high SPRAY TOPICORT 0.05% GM CREAM Medium 460 DESOXIMETASONE 0.05% GM CREAM TOPICORT 0.25% GM CREAM High 460 DESOXIMETASONE 0.25% GM CREAM TOPICORT 0.05% GM High 460 GEL Topical Corticosteroids FEP Clinical Criteria DESOXIMETASONE 0.05% GM GEL TOPICORT 0.05% GM OINTMENT High 460 DESOXIMETASONE 0.05% GM OINTMENT TOPICORT 0.25% GM OINTMENT High 460 DESOXIMETASONE 0.25% GM OINTMENT DIFLORASONE 3 MONTH Strength UOM Potency DIACETATE LIMIT PSORCON 0.05% GM CREAM High 460 DIFLORASONE 0.05% GM CREAM DIFLORASONE Very 0.05% GM 460 OINTMENT high APEXICON E 0.05% GM High 460 CREAM FLUOCINOLONE 3 MONTH Strength UOM Potency ACETONIDE LIMIT DERMA-SMOOTH /FS 0.01% ML BODY OIL Low to 460 FLUOCINOLONE medium 0.01% ML BODY OIL DERMA-SMOOTH /FS 0.01% ML SCALP OIL Low to 460 FLUOCINOLONE medium 0.01% ML SCALP OIL SYNALAR 0.01% ML SOLUTION Low 460 FLUOCINOLONE 0.01% ML SOLUTION FLUOCINOLONE 0.01% GM Low 460 CREAM SYNALAR 0.025% GM CREAM Medium 460 FLUOCINOLONE 0.025% GM CREAM SYNALAR 0.025% GM OINTMENT Medium 460 FLUOCINOLONE 0.025% GM OINTMENT CAPEX Low to 0.01% ML 460 SHAMPOO Medium 3 MONTH FLUOCINONIDE Strength UOM Potency LIMIT FLUOCINONIDE 0.05% ML High 460 SOLUTION FLUOCINONIDE 0.05% GM High 460 CREAM Topical Corticosteroids FEP Clinical Criteria FLUOCINONIDE 0.05% GM High 460 GEL FLUOCINONIDE 0.05% GM High 460 OINTMENT FLUOCINONIDE-E 0.05% GM High 460 EMULSIFIED CREAM FLUOCINONIDE Very 0.1% GM 460 CREAM high FLUOCINONIDE Very 0.1% GM 460 GEL high FLUOCINONIDE Very 0.1% GM 460 OINTMENT high FLUOCINONIDE Very 0.1% GM 460 SOLUTION high 3 MONTH FLURANDRENOLIDE Strength UOM Potency LIMIT CORDRAN 0.025% GM High 460 CREAM CORDRAN 0.05% GM CREAM High 460 NOLIX 0.05% GM CREAM CORDRAN 0.05% ML LOTION High 460 NOLIX 0.05% ML LOTION CORDRAN 0.05% GM OINTMENT High 460 FLURANDRENOLIDE 0.05% GM OINTMENT CORDRAN 4 MCG EA High 2 Rolls TAPE FLUTICASONE 3 MONTH Strength UOM Potency PROPIONATE LIMIT FLUTICASONE 0.05% GM Medium 460 CREAM CUTIVATE 0.05% ML LOTION Medium 460 FLUTICASONE 0.05% ML LOTION FLUTICASONE 0.005% GM Medium 460 OINTMENT 3 MONTH HALCINONIDE Strength UOM Potency LIMIT HALOG 0.1% GM High 460 CREAM HALOG 0.1% GM High 460 OINTMENT HALOG 0.1% ML High 460 SOLUTION HALOBETASOL 3 MONTH Strength UOM Potency PROPIONATE LIMIT Topical Corticosteroids FEP Clinical Criteria ULTRAVATE 0.05% GM CREAM HALOBETASOL Very 0.05% GM 460 CREAM high HALOBETASOL 0.05% GM AEROSOL FOAM ULTRAVATE Very 0.05% ML 460 LOTION high ULTRAVATE 0.05% GM OINTMENT Very 460 HALOBETASOL high 0.05% GM OINTMENT 3 MONTH HYDROCORTISONE Strength UOM Potency LIMIT TEXACORT 2.5% ML Low 460 SOLUTION HYDROCORTISONE 1% GM Low 460 CREAM HYDROCORTISONE 2.5% GM Low 460 CREAM ALA SCALP 2% ML Low 460 LOTION HYDROCORTISONE 2.5% ML Low 460 LOTION HYDROCORTISONE 1% GM Low 460 OINTMENT HYDROCORTISONE 2.5% GM Low 460 OINTMENT HYDROCORTISONE 3 MONTH Strength UOM Potency ACETATE LIMIT MICORT-HC 2.5% GM Low 460 CREAM HYDROCORTISONE 3 MONTH Strength UOM Potency VALERATE LIMIT HYDROCORTISONE VALERATE 0.2% GM Medium 460 CREAM WESTCORT 0.2% GM OINTMENT Medium 460 HYDROCORTISONE VALERATE 0.2% GM OINTMENT 3 MONTH HYDROCORTISONE PROBUTATE Strength UOM Potency LIMIT PANDEL 0.1% GM Medium 460 CREAM HYDROCORTISONE 3 MONTH Strength UOM Potency BUTYRATE LIMIT LOCOID 0.1% ML SOLUTION Medium 460 HYDROCORTISONE BUTYRATE 0.10% ML SOLUTION LOCOID 0.1% GM Medium 460 CREAM Topical Corticosteroids FEP Clinical Criteria HYDROCORTISONE BUTYRATE 0.1% GM CREAM LOCOID 0.1% ML LOTION Medium 460 HYDROCORTISONE 0.1% ML LOTION LOCOID 0.1% GM OINTMENT Medium 460 HYDROCORTISONE BUTYRATE 0.1% GM OINTMENT LOCOID 0.1% GM HYDROPHILIC LIPOCREAM Medium 460 HYDROCORTISONE BUTYRATE 0.10% GM HYDROPHILIC LIPOCREAM MOMETASONE 3 MONTH Strength UOM Potency FUROATE LIMIT MOMETASONE 0.1% ML Medium 460 SOLUTION ELOCON 0.1% GM CREAM Medium 460 MOMETASONE 0.1% GM CREAM ELOCON 0.1% GM OINTMENT Medium 460 MOMETASONE 0.1% GM OINTMENT 3 MONTH PREDNICARBATE Strength UOM Potency LIMIT PREDNICARBATE 0.1% GM Medium 460 CREAM DERMATOP 0.1% GM OINTMENT Medium 460 PREDNICARBATE 0.1% GM OINTMENT TRIAMCINOLONE 3 MONTH Strength UOM Potency ACETONIDE LIMIT KENALOG SPRAY GM AEROSOL SPRAY High 460 TRIAMCINOLONE SPRAY GM AEROSOL SPRAY TRIAMCINOLONE 0.025% GM Medium 460 CREAM TRIAMCINOLONE 0.1% GM Medium 460 CREAM TRIAMCINOLONE 0.5% GM High 460 CREAM TRIAMCINOLONE 0.025% ML Medium 460 LOTION TRIAMCINOLONE 0.1% ML Medium 460 LOTION TRIAMCINOLONE 0.025% GM Medium 460 OINTMENT Topical Corticosteroids FEP Clinical Criteria TRIANEX 0.05% GM Medium None OINTMENT TRIAMCINOLONE 0.1% GM Medium 460 OINTMENT TRIAMCINOLONE 0.5% GM High 460 OINTMENT ➢ Pre-PA quantity limit allows for the American Academy of Dermatology (AAD) recommended dosage.
Load more

Recommended publications
  • Trihydroxyisoflavone Improves Skin Barrier Function Impaired by E
    www.nature.com/scientificreports OPEN A novel mineralocorticoid receptor antagonist, 7,3’,4’‑trihydroxyisofavone improves skin barrier function impaired by endogenous or exogenous glucocorticoids Hanil Lee1,5, Eun‑Jeong Choi2,5, Eun Jung Kim1, Eui Dong Son2, Hyoung‑June Kim2, Won‑Seok Park2, Young‑Gyu Kang2, Kyong‑Oh Shin3, Kyungho Park3, Jin‑Chul Kim4, Su‑Nam Kim4 & Eung Ho Choi1* Excess glucocorticoids (GCs) with either endogenous or exogenous origins deteriorate skin barrier function. GCs bind to mineralocorticoid and GC receptors (MRs and GRs) in normal human epidermal keratinocytes (NHEKs). Inappropriate MR activation by GCs mediates various GC‑induced cutaneous adverse events. We examined whether MR antagonists can ameliorate GC‑mediated skin barrier dysfunction in NHEKs, reconstructed human epidermis (RHE), and subjects under psychological stress (PS). In a preliminary clinical investigation, topical MR antagonists improved skin barrier function in topical GC‑treated subjects. In NHEKs, cortisol induced nuclear translocation of GR and MR, and GR and MR antagonists inhibited cortisol‑induced reductions of keratinocyte diferentiation. We identifed 7,3’,4’‑trihydroxyisofavone (7,3’,4’‑THIF) as a novel compound that inhibits MR transcriptional activity by screening 30 cosmetic compounds. 7,3’,4’‑THIF ameliorated the cortisol efect which decreases keratinocyte diferentiation in NHEKs and RHE. In a clinical study on PS subjects, 7,3’,4’‑ THIF (0.1%)‑containing cream improved skin barrier function, including skin surface pH, barrier recovery rate, and stratum corneum lipids. In conclusion, skin barrier dysfunction owing to excess GC is mediated by MR and GR; thus, it could be prevented by treatment with MR antagonists. Therefore, topical MR antagonists are a promising therapeutic option for skin barrier dysfunction after topical GC treatment or PS.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al
    US 20080317805A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 McKay et al. (43) Pub. Date: Dec. 25, 2008 (54) LOCALLY ADMINISTRATED LOW DOSES Publication Classification OF CORTICOSTEROIDS (51) Int. Cl. A6II 3/566 (2006.01) (76) Inventors: William F. McKay, Memphis, TN A6II 3/56 (2006.01) (US); John Myers Zanella, A6IR 9/00 (2006.01) Cordova, TN (US); Christopher M. A6IP 25/04 (2006.01) Hobot, Tonka Bay, MN (US) (52) U.S. Cl. .......... 424/422:514/169; 514/179; 514/180 (57) ABSTRACT Correspondence Address: This invention provides for using a locally delivered low dose Medtronic Spinal and Biologics of a corticosteroid to treat pain caused by any inflammatory Attn: Noreen Johnson - IP Legal Department disease including sciatica, herniated disc, Stenosis, mylopa 2600 Sofamor Danek Drive thy, low back pain, facet pain, osteoarthritis, rheumatoid Memphis, TN38132 (US) arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural (21) Appl. No.: 11/765,040 space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug (22) Filed: Jun. 19, 2007 depot. E Day 7 8 Day 14 El Day 21 3OO 2OO OO OO Control Dexamethasone DexamethasOne Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr 0.0032ng/hr 0.016 ng/hr 0.08 ng/hr Patent Application Publication Dec. 25, 2008 Sheet 1 of 2 US 2008/0317805 A1 900 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 80.0 - 7OO – 6OO - 5OO - E Day 7 EDay 14 40.0 - : El Day 21 2OO - OO = OO – Dexamethasone Dexamethasone Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr O.OO32ng/hr O.016 ng/hr 0.08 nghr Patent Application Publication Dec.
    [Show full text]
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • Betamethasone
    Betamethasone Background Betamethasone is a potent, long-acting, synthetic glucocorticoid widely used in equine veterinary medicine as a steroidal anti-inflammatory.1 It is often administered intra-articularly for control of pain associated with inflammation and osteoarthritis.2 Betamethasone is a prescription medication and can only be dispensed from or upon the request of a http://en.wikipedia.org/wiki/Betamethasone#/media/File:Betamethasone veterinarian. It is commercially available .png in a variety of formulations including BetaVet™, BetaVet Soluspan Suspension® and Betasone Aqueous Suspension™.3 Betamethasone can be used intra-articularly, intramuscularly, by inhalation, and topically.4 When administered intra-articularly, it is often combined with other substances such as hyaluronan.5 Intra-articular and intramuscular dosages range widely based upon articular space, medication combination protocol, and practitioner preference. Betamethasone is a glucocorticoid receptor agonist which binds to various glucocorticoid receptors setting off a sequence of events affecting gene transcription and the synthesis of proteins. These mechanisms of action include: • Potential alteration of the G protein-coupled receptors to interfere with intracellular signal transduction pathways • Enhanced transcription in many genes, especially those involving suppression of inflammation. • Inhibition of gene transcription – including those that encode pro-inflammatory substances. The last two of these are considered genomic effects. This type of corticosteroid effect usually occurs within hours to days after administration. The genomic effects persist after the concentrations of the synthetic corticosteroid in plasma are no longer detectable, as evidenced by persistent suppression of the normal production of hydrocortisone following synthetic corticosteroid administration.6 When used judiciously, corticosteroids can be beneficial to the horse.
    [Show full text]
  • DESONATE® (Desonide) Gel 0.05% for Topical Use Only • Systemic Absorption May Require Evaluation for HPA Axis Suppression Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------- WARNINGS AND PRECAUTIONS------------------------ These highlights do not include all the information needed to use • Topical corticosteroids can produce reversible hypothalamic pituitary DESONATE Gel safely and effectively. See full prescribing information adrenal (HPA) axis suppression, Cushing's syndrome and unmask latent for DESONATE Gel. diabetes. (5.1) DESONATE® (desonide) Gel 0.05% for topical use only • Systemic absorption may require evaluation for HPA axis suppression Initial U.S. Approval: 1972 (5.1). • Modify use should HPA axis suppression develop (5.1) ---------------------------- INDICATIONS AND USAGE--------------------------- • Potent corticosteroids, use on large areas, prolonged use or occlusive use may increase systemic absorption (5.1) DESONATE is a corticosteroid indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. (1) • Local adverse reactions may include atrophy, striae, irritation, acneiform eruptions, hypopigmentation, and allergic contact dermatitis and may be ---------------------- DOSAGE AND ADMINISTRATION----------------------- more likely with occlusive use or more potent corticosteroids. (5.2, 5.4, 6) • Apply as a thin layer to the affected areas two times daily and rub in • Children may be more susceptible to systemic toxicity when treated with gently. (2) topical corticosteroids. (5.1, 8.4) • Therapy should be discontinued when control is achieved. (2) • If no improvement is seen within 4 weeks, reassessment of diagnosis ------------------------------ ADVERSE REACTIONS------------------------------- may be necessary. (2) The most common adverse reactions (incidence ≥ 1%) are headache and • Should not be used with occlusive dressings. (2) application site burning. (6) • Treatment beyond 4 consecutive weeks is not recommended. (2) To report SUSPECTED ADVERSE REACTIONS, contact LEO Pharma • For topical use only.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Clinical Policy: Topical Agents: Corticosteroids
    Clinical Policy: Topical Agents: Corticosteroids Reference Number: OH.PHAR.PPA.92 Effective Date: 01/01/2020 Revision Log Last Review Date: Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description TOPICAL AGENTS: CORTICOSTEROIDS – LOW POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON- PREFERRED” DESONIDE cream, ointment (generic of Desowen®) ALCLOMETASONE cream, ointment (generic of FLUOCINOLONE ACETONIDE 0.01% cream, solution Aclovate®) (generic of Synalar®) CAPEX® shampoo (fluocinolone acetonide) FLUOCINOLONE body oil, scalp oil (generic of Derma- DESONATE®gel (desonide) Smoothe/ FS®) DESONIDE lotion (generic of Desowen®) HYDROCORTISONE cream, lotion, ointment HYDROCORTISONE ACETATE WITH ALOE gel HYDROCORTISONE WITH UREA cream (generic of Carmol HC®) PANDEL® cream (hydrocortisone probutate) PEDIADERM HC® kit TOPICAL AGENTS: CORTICOSTEROIDS – MEDIUM POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON--PREFERRED” BETAMETHASONE DIPROPIONATE-CALCIPOTRIENE BETAMETHASONE DIPROPIONATE lotion (generic of Ointment Diprolene®) BETAMETHASONE VALERATE cream, lotion (generic of CLOCORTOLONE PIVALATE (generic of Cloderm®) Valisone®) CORDRAN® tape (flurandrenolide) FLUTICASONE PROPIONATE cream, ointment (generic of DESOXIMETASONE cream, gel, ointment (generic of Cutivate®) Topicort®) MOMETASONE FUROATE cream, ointment, solution FLUOCINOLONE ACETONIDE 0.025% cream, ointment (generic of Elocon®) (generic of Synalar®) PREDNICARBATE cream (generic of Dermatop®) FLUTICASONE
    [Show full text]
  • Orange Book Cumulative Supplement 7 July 2006
    CUMULATIVE SUPPLEMENT 07 July 2006 APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 26th EDITION Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research Office of Generic Drugs 2006 Prepared By Office of Generic Drugs Center for Drug Evaluation and Research Food and Drug Administration APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 26th EDITION Cumulative Supplement 07 July 2006 CONTENTS PAGE 1.0 INTRODUCTION ........................................................................................................................................ iii 1.1 How to use the Cumulative Supplement ........................................................................................... iii 1.2 Applicant Name Changes.................................................................................................................. iv 1.3 Availability of the Edition ................................................................................................................... vi 1.4 Report of Counts for the Prescription Drug Product List ................................................................... vi 1.5 Zocor (simvastatin) Patent Relisting.................................................................................................viii 1.6 Cumulative Supplement Legend ....................................................................................................... vi DRUG PRODUCT LISTS Prescription Drug Product List ......................................................................................................
    [Show full text]
  • Steroids Topical
    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
    [Show full text]
  • Formulary Updates Effective January 1, 2021
    Formulary Updates Effective January 1, 2021 Dear Valued Client, Please see the following lists of formulary updates that will apply to the HometownRx Formulary effective January 1 st , 2021. As the competition among clinically similar products increases, our formulary strategy enables us to prefer safe, proven medication alternatives and lower costs without negatively impacting member choice or access. Please note: Not all drugs listed may be covered under your prescription drug benefit. Certain drugs may have specific restrictions or special copay requirements depending on your plan. The formulary alternatives listed are examples of selected alternatives that are on the formulary. Other alternatives may be available. Members on a medication that will no longer be covered may want to talk to their healthcare providers about other options. Medications that do not have alternatives will be available at 100% member coinsurance . Preferred to Non -Preferred Tier Drug Disease State /Drug Class Preferred Alternatives ALREX Eye inflammation loteprednol (generic for LOTEMAX) APRISO 1 Gastrointestinal agent mesalamine (generic for APRISO) BEPREVE Eye allergies azelastine (generic for OPTIVAR) CIPRODEX 1 Ear inflammation ciprofloxacin-dexamethasone (generic for CIPRODEX) COLCRYS 1 Gout colchicine (generic for COLCRYS) FIRST -LANSOPRAZOLE Gastrointestinal agent Over-the-counter lansoprazole without a prescription FIRST -MOUTHWASH BLM Mouth inflammation lidocaine 2% viscous solution (XYLOCAINE) LOTEMAX 1 Eye inflammation loteprednol etabonate (generic
    [Show full text]
  • Medication List
    Medication List Walgreens Plus™ members receive discounts on thousands of generic and brand-name medications included on this Medication List, which is divided into two sections, “Value Priced” Medications and “Discounted” Medications*. The price for a medication identified as “Value-Priced” is listed below: Get savings up to 85% off Cash Prices • 30-day-supply drugs cost $5 (tier 1), $10 (tier 2) or $15 (tier 3) on Atorvastatin (generic Lipitor) and • 90-day-supply drugs cost $10 (tier 1), $20 (tier 2) or $30 (tier 3) Rosuvastatin (generic Crestor) †† The Discounted Medications section lists the discounts offered to Walgreens Plus members on other generic and brand-name medications not included in the Value-Priced Medication section. The price for a medication is based on its tier and whether it is a 30-day or 90-day supply†. There may be an additional cost for quanities greater than those listed. This discount prescription pricing applies only to Walgreen Plus members on prescriptions purchased in select Walgreens stores that are not billed to insurance and/or used in combination with other health or pharmacy benefit programs. For further details, see your pharmacist or Walgreens.com/Plus. VALUE GENERICS NAPROXEN 250MG TAB 2 60 180 Antifungal NAPROXEN 500MG TAB 2 60 180 Quantity NAPROXEN 375MG TAB 2 60 180 Drug Name Tier 30 90 NAPROXEN DR 500MG TAB 3 60 180 FLUCONAZOLE 150MG TAB 2 1 3 TERBINAFINE 250MG TAB 2 30 90 Asthma Quantity Antiviral Drug Name Tier 30 90 Quantity ALBUTEROL 0.083% INH SOLN 25X3ML 2 75 225 Drug Name Tier 30 90 AMINOPHYLLINE
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]